Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is alveolar soft part sarcoma?
Alveolar soft part sarcoma (ASPS) is a rare type of soft-tissue sarcoma — a cancer that begins in the body's connective tissues rather than in an organ lining. It most often affects teenagers and young adults, and in younger patients it tends to appear in the muscles of an arm or leg, while in adults it is also found in the trunk. Under the microscope its cells cluster into little nests that look like the air sacs (alveoli) of the lung, which is where its name comes from. ASPS is driven by a specific genetic change — a fusion of two genes called ASPSCR1 and TFE3 — that switches on signals telling the tumor to build new blood vessels. That rich blood supply helps explain two of its defining features: it grows slowly, often as a painless mass that a person may notice for months or even years before diagnosis, yet it readily releases cells into the bloodstream that travel to distant organs, especially the lungs and the brain. Because it can spread early and silently, many patients already have small deposits in the lungs when the original tumor is found. Unlike many sarcomas, ASPS does not respond well to traditional chemotherapy, so management depends on removing the original tumor completely, using radiation to control microscopic disease and reduce the chance of it returning where it started, and — for disease that has spread — newer medicines that block blood-vessel growth or harness the immune system, which have changed the outlook for this cancer in recent years.
The main types
Doctors group alveolar soft part sarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Localized alveolar soft part sarcoma | The tumor is confined to where it started, usually a deep muscle in a limb or the trunk; it can often be removed completely, giving the best chance of long-term control. |
| Metastatic alveolar soft part sarcoma | The cancer has spread, most often to the lungs and sometimes the brain or bone; because the disease usually grows slowly, people can live for years, and modern targeted and immune therapies can control it for long periods. |
Staging, in plain terms
ASPS is formally staged with the soft-tissue sarcoma TNM system, which considers the size and depth of the tumor (T), whether nearby lymph nodes are involved (N), and whether the cancer has spread to distant organs (M), together with the tumor grade. In practice, though, ASPS behaves in its own way, so the stage number tells only part of the story. The single most important question is whether the disease is still confined to where it started or has already traveled to distant sites — most often the lungs, and less commonly the brain or bone. Because ASPS can seed the bloodstream early and grow slowly once it lands, doctors look carefully at the lungs with a CT scan and often image the brain at diagnosis, even when the original tumor seems small and causes no symptoms. The pace of the disease is unusual: a person can have small lung deposits that change very little for a long time. That is why treatment decisions weigh not just the formal stage but how the cancer is behaving — how many deposits there are, where they sit, whether they are growing, and whether they can be removed or focally treated.
| Soft-tissue sarcoma TNM with grade, but behavior matters more than the number — the key questions are whether it is confined to one site or has already spread, and whether deposits are present in the lungs or brain | What it generally means |
|---|---|
| Localized, completely removable | The tumor is confined to its site and can be taken out with a margin of healthy tissue; surgery, often combined with radiation, offers the best chance of lasting local control. |
| Localized, difficult to remove | The tumor sits near important nerves, vessels, or in a hard-to-reach spot; radiation is used alongside surgery — before or after — to control disease that can't be fully cut out. |
| Oligometastatic (a few distant spots) | A limited number of deposits, usually in the lungs; these can sometimes be removed surgically or treated with focused high-dose radiation, sometimes alongside targeted or immune therapy. |
| Widely metastatic | More extensive spread; managed mainly with medicines that block blood-vessel growth or activate the immune system, with surgery or focused radiation for problem spots. |
The standard of care
Alveolar Soft Part Sarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Complete surgical removal
Taking out the original tumor with a margin of healthy tissue is the foundation of treatment for disease that hasn't spread, and gives the best chance of controlling it where it began.
Radiation therapy (with surgery)
Given before or after surgery to treat the microscopic disease that extends beyond the visible tumor; it lowers the chance of the cancer returning at the original site and can make a complete, function-preserving operation more achievable.
Targeted antiangiogenic therapy
Pills that block the formation of the new blood vessels ASPS depends on can shrink or stabilize tumors that have spread; this class of drug has become a mainstay for metastatic disease.
Immunotherapy
Medicines that release the brakes on the immune system have produced meaningful, sometimes durable responses in ASPS, which is unusually responsive to this approach for a sarcoma.
Treatment of limited metastases
Because ASPS often grows slowly, a small number of lung or brain deposits can be removed surgically or treated with focused high-dose radiation, sometimes giving years of control.
Sarcoma specialty center care
This is a rare cancer, and care at a center with a dedicated sarcoma team — for accurate diagnosis, the right surgery, and access to the newest therapies and trials — gives the best outcomes.
How radiation treatment works
Radiation therapy treats alveolar soft part sarcoma by delivering precisely aimed beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. It plays two distinct roles in this disease. The first is local control of the original tumor. Like other soft-tissue sarcomas, ASPS doesn't stay neatly inside the visible mass — it pushes microscopic fingers of tumor into the surrounding muscle and connective tissue. If only the obvious tumor were removed, those microscopic extensions could be left behind and regrow. Radiation treats a wider zone around the tumor, sterilizing that microscopic disease so the operation can be smaller and more likely to preserve the limb, and so the cancer is far less likely to return at the original site. It can be given before surgery, using a smaller area and lower dose and sometimes shrinking the tumor to make removal easier, or after surgery to the tumor bed at a higher dose when needed. The second role is treating the distant deposits ASPS is prone to form. Because this cancer tends to grow slowly, a limited number of spots in the lungs or brain can often be controlled for a long time with focused, high-dose radiation rather than ongoing drug therapy alone. Stereotactic radiosurgery delivers a concentrated dose to a brain metastasis in one or a few sessions while sparing the surrounding brain, and stereotactic body radiation does the same for lung deposits. This matters especially for ASPS because traditional chemotherapy is largely ineffective against it, so radiation — alongside surgery, antiangiogenic pills, and immunotherapy — is one of the most reliable tools for keeping the disease in check at specific sites.
The main ways radiation is delivered for alveolar soft part sarcoma:
Preoperative (neoadjuvant) radiation
Radiation before surgery treats the rim of microscopic disease using a smaller field and lower dose, and can make a complete, limb-preserving removal more achievable.
Postoperative (adjuvant) radiation
Radiation to the tumor bed after surgery sterilizes any microscopic disease left behind, lowering the chance of the cancer returning at the original site, especially when margins are close.
Stereotactic radiosurgery (SRS) for brain metastases
Highly focused, high-dose radiation delivered in one or a few sessions can control brain deposits precisely while sparing surrounding healthy brain — important because ASPS has a particular tendency to reach the brain.
Stereotactic body radiation (SBRT) for lung metastases
Focused, high-dose beams can ablate a limited number of lung deposits without surgery, providing durable control of the slow-growing spots ASPS typically forms.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Immunotherapy is unusually active in ASPS: Clinical trials show that immune checkpoint inhibitors produce meaningful and sometimes durable tumor shrinkage in alveolar soft part sarcoma — a striking result for a sarcoma — making immunotherapy a key option for advanced disease.[1]
Checkpoint inhibitor trials in alveolar soft part sarcoma
Antiangiogenic targeted therapy controls metastatic disease: Because ASPS depends heavily on building new blood vessels, drugs that block this process can shrink or stabilize tumors that have spread, and are now a standard approach for metastatic ASPS.[2]
Antiangiogenic tyrosine kinase inhibitor studies in ASPS
Focused radiation and surgery for limited metastases: Because ASPS usually grows slowly, removing or precisely irradiating a small number of lung or brain deposits can achieve long-term control, supporting an aggressive local approach to oligometastatic disease.[3]
Metastasis-directed therapy series in slow-growing sarcomas
Common questions
Why is alveolar soft part sarcoma watched so carefully for spread when it grows slowly? Because slow growth and a tendency to spread are not opposites in this cancer — they happen together. ASPS often grows quietly at its original site for months or years, but it also releases cells into the bloodstream early, and those cells settle most often in the lungs and sometimes the brain, where they too may grow slowly. As a result, many people already have small distant deposits when the original tumor is found, even with no symptoms. That is why doctors scan the lungs and often image the brain at diagnosis and during follow-up — finding deposits while they are few and small makes it possible to remove them or treat them with focused radiation and achieve long-term control.
If chemotherapy doesn't work well, what treats ASPS? ASPS is one of the sarcomas that responds poorly to traditional chemotherapy, so treatment relies on other tools. For disease confined to one site, surgery to remove the tumor completely — usually combined with radiation to control microscopic disease — is the foundation. For disease that has spread, two newer approaches have changed the outlook: targeted pills that block the tumor's ability to build new blood vessels, and immunotherapy that activates the immune system against the cancer, which is unusually effective in ASPS. Focused high-dose radiation and surgery are also used to control a limited number of distant spots.
Can radiation treat ASPS that has spread to the brain or lungs? Yes. Because ASPS tends to grow slowly, a limited number of deposits can often be controlled for a long time with focused, high-dose radiation rather than surgery. For the brain, stereotactic radiosurgery delivers a concentrated dose to a deposit in one or a few sessions while sparing the surrounding brain. For the lungs, stereotactic body radiation can ablate a small number of spots without an operation. These targeted treatments are frequently combined with antiangiogenic or immune therapy, and for some people they provide years of control.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Checkpoint inhibitor trials in alveolar soft part sarcoma (no indexed identifier — see your care team) ↩
- Antiangiogenic tyrosine kinase inhibitor studies in ASPS (no indexed identifier — see your care team) ↩
- Metastasis-directed therapy series in slow-growing sarcomas (no indexed identifier — see your care team) ↩